Pfizer Other Non-Current Liabilities 2010-2024 | PFE
Pfizer other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Pfizer other non-current liabilities for the quarter ending September 30, 2024 were $21.474B, a 3.88% decline year-over-year.
- Pfizer other non-current liabilities for 2023 were $25.073B, a 9.05% increase from 2022.
- Pfizer other non-current liabilities for 2022 were $22.992B, a 9.1% increase from 2021.
- Pfizer other non-current liabilities for 2021 were $21.074B, a 15.61% increase from 2020.
Pfizer Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$25,073 |
| 2022 |
$22,992 |
| 2021 |
$21,074 |
| 2020 |
$18,229 |
| 2019 |
$19,020 |
| 2018 |
$20,587 |
| 2017 |
$24,846 |
| 2016 |
$10,337 |
| 2015 |
$9,249 |
| 2014 |
$9,236 |
| 2013 |
$8,760 |
| 2012 |
$11,432 |
| 2011 |
$12,986 |
| 2010 |
$11,846 |
| 2009 |
$14,611 |
Pfizer Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$21,474 |
| 2024-06-30 |
$22,627 |
| 2024-03-31 |
$23,725 |
| 2023-12-31 |
$25,073 |
| 2023-09-30 |
$22,341 |
| 2023-06-30 |
$21,455 |
| 2023-03-31 |
$22,869 |
| 2022-12-31 |
$22,992 |
| 2022-09-30 |
$21,940 |
| 2022-06-30 |
$22,301 |
| 2022-03-31 |
$22,082 |
| 2021-12-31 |
$21,074 |
| 2021-09-30 |
$20,537 |
| 2021-06-30 |
$19,487 |
| 2021-03-31 |
$18,436 |
| 2020-12-31 |
$18,229 |
| 2020-09-30 |
$18,571 |
| 2020-06-30 |
$18,280 |
| 2020-03-31 |
$19,024 |
| 2019-12-31 |
$19,020 |
| 2019-09-30 |
$18,885 |
| 2019-06-30 |
$18,604 |
| 2019-03-31 |
$21,058 |
| 2018-12-31 |
$20,587 |
| 2018-09-30 |
$21,656 |
| 2018-06-30 |
$21,544 |
| 2018-03-31 |
$22,249 |
| 2017-12-31 |
$24,846 |
| 2017-09-30 |
$10,692 |
| 2017-06-30 |
$10,536 |
| 2017-03-31 |
$10,945 |
| 2016-12-31 |
$10,337 |
| 2016-09-30 |
$10,826 |
| 2016-06-30 |
$9,634 |
| 2016-03-31 |
$9,233 |
| 2015-12-31 |
$9,249 |
| 2015-09-30 |
$9,439 |
| 2015-06-30 |
$9,669 |
| 2015-03-31 |
$9,937 |
| 2014-12-31 |
$9,236 |
| 2014-09-30 |
$8,196 |
| 2014-06-30 |
$8,038 |
| 2014-03-31 |
$8,200 |
| 2013-12-31 |
$8,760 |
| 2013-09-30 |
$11,539 |
| 2013-06-30 |
$12,050 |
| 2013-03-31 |
$11,899 |
| 2012-12-31 |
$11,432 |
| 2012-09-30 |
$11,272 |
| 2012-06-30 |
$12,935 |
| 2012-03-31 |
$12,103 |
| 2011-12-31 |
$12,986 |
| 2011-09-30 |
$13,139 |
| 2011-06-30 |
$11,761 |
| 2011-03-31 |
$11,560 |
| 2010-12-31 |
$11,846 |
| 2010-09-30 |
$14,771 |
| 2010-06-30 |
$15,188 |
| 2010-03-31 |
$14,008 |
| 2009-12-31 |
$14,611 |
| 2009-09-30 |
$9,979 |
| 2009-06-30 |
$10,014 |
| 2009-03-31 |
$9,596 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$145.358B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
